To determine how tumor cell USP18 affects these cells and thus the immune response, we injected B16-OVA-GFP or B16-OVA-USP18 tumor cells into C57BL/6 mice that were depleted of CD4+ or CD8+ T cells or NK cells and monitored tumorigenesis. This evidence concerns the gene CD8A and neoplasm.